AbbVie Invests an Additional $223 Million in Singapore Manufacturing Plant
The latest financial commitment adds 24,000 liters of biologics drug substance-capacity to the company’s network.
AbbVie will be growing its Singapore manufacturing facility with a new $223 million expansion project that is expected to begin later this year, marking a total investment of over $740 million on this plant over the past decade. The investment—which will see the new facilities become operational by 2026— is expected to add more than 100 jobs in administration, engineering, manufacturing, quality assurance, and supply chain.
The Singapore plant is AbbVie’s only manufacturing site in Asia. It is housed in Tuas Biomedical Park, and serves as a state-of-the-art small-molecule and biologics manufacturing plant. This new financial commitment will add 24,000 liters of biologics drug-substance capacity to AbbVie's global manufacturing network, while also supporting both current products and upcoming immunology and oncology compounds.
"This expansion announcement represents one of AbbVie's many investments in its Singapore-based operations and the proud continuation of our decade-long partnership with the Government of Singapore," says Azita Saleki-Gerhardt, PhD, AbbVie’s EVP and COO. "The expansion of our Singapore site will strengthen our global manufacturing capabilities, support our growing biologics pipeline, and help AbbVie continue delivering on our patient commitments now and in the future."
Reference
AbbVie Expands Biologics Manufacturing Capacity with a $223 Million Investment in Singapore Manufacturing Site. AbbVie. January 25, 2024. Accessed January 30, 2024. https://news.abbvie.com/2024-01-26-AbbVie-Expands-Biologics-Manufacturing-Capacity-with-a-223-Million-Investment-in-Singapore-Manufacturing-Site
